Johnson & Johnson (NYSE:JNJ) announces a quarterly dividend of $0.96



Johnson & Johnson (NYSE:JNJ) to go ex-dividend.
On 4/25/2019 Johnson & Johnson ( NYSE:JNJ ) announced that it will be issuing a quarterly dividend in the amount of $0.96 down from $0.96 making the yield 2.76%.


Johnson & Johnson (NYSE:JNJ) Ex- dividend date

Johnson & Johnson (NYSE:JNJ) is set to go ex-dividend on 5/24/2019 and will be payable on 6/11/2019


Dividend History for Johnson & Johnson (NYSE:JNJ)
The next payable dividend for Johnson & Johnson is scheduled for 6/11/2019. There is an annual dividend of $$3.60 with a yield of 2.58% The company’s dividend has increased by 6.30% on a 3 Year Average

Recent Dividend History for Johnson & Johnson (NYSE:JNJ)

  • On 1/2/2013 Johnson & Johnson announced a quarterly dividend of $0.61.
  • On 4/25/2013 Johnson & Johnson announced a quarterly dividend of $0.66.
  • On 7/15/2013 Johnson & Johnson announced a quarterly dividend of $0.66.
  • On 10/17/2013 Johnson & Johnson announced a quarterly dividend of $0.66.
  • On 1/2/2014 Johnson & Johnson announced a quarterly dividend of $0.66.
  • On 4/24/2014 Johnson & Johnson announced a quarterly dividend of $0.70.
Story continues below



About Company
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular diseases; sterilization and disinfection products to reduce surgical infection; diabetes care products; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. It has research and collaboration alliance with Morphic Therapeutic. The company was incorporated in 1887 and is based in New Brunswick, New Jersey.

Recent Insider Trading for Johnson & Johnson (NYSE:JNJ)

  • On 12/14/2018 Charles Prince, Director, bought 2,000 with an average share price of $134.37 per share and the total transaction amounting to $268,740.00.
  • On 12/13/2018 Ronald A Kapusta, CAO, sold 3,643 with an average share price of $147.31 per share and the total transaction amounting to $536,650.33.
  • On 12/4/2018 Peter Fasolo, VP, sold 166,695 with an average share price of $146.41 per share and the total transaction amounting to $24,405,814.95.
  • On 11/23/2018 Michael E Sneed, EVP, sold 30,943 with an average share price of $142.46 per share and the total transaction amounting to $4,408,139.78.
  • On 11/16/2018 Alex Gorsky, CEO, sold 264,465 with an average share price of $145.96 per share and the total transaction amounting to $38,601,311.40.
  • On 11/8/2018 Ronald A Kapusta, CAO, sold 8,441 with an average share price of $145.15 per share and the total transaction amounting to $1,225,211.15.



Recent Analyst Rating for Johnson & Johnson (NYSE:JNJ)

  • On 4/17/2019 BMO Capital Markets, Boost Price Target, fromOutperform to Outperform with a price target of $154.00 to $157.00
  • On 4/17/2019 Credit Suisse Group, Boost Price Target, fromOutperform to Outperform with a price target of $151.00 to $152.00
  • On 4/17/2019 Morgan Stanley, Boost Price Target, fromEqual Weight to Equal Weight with a price target of $134.00 to $145.00
  • On 4/17/2019 Raymond James, Boost Price Target, fromOutperform to Outperform with a price target of $145.00 to $147.00
  • On 2/25/2019 Citigroup, Boost Price Target, fromNeutral to Neutral with a price target of $139.00 to $147.00
  • On 1/23/2019 Barclays, Reiterated Rating, fromEqual Weight to Equal Weight with a price target of $137.00 to $135.00



Recent Trading for Johnson & Johnson (NYSE:JNJ)
Shares of Johnson & Johnson closed the previous trading session at with shares trading hands.

An ad to help with our costs